AAAAAA
Results:
1-7
|
Results: 7
Authors:
Xiang, R
Silletti, S
Lode, HN
Dolman, CS
Ruehlmann, JM
Niethammer, AG
Pertl, U
Gillies, SD
Primus, FJ
Reisfeld, RA
Citation: R. Xiang et al., Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice, CLIN CANC R, 7(3), 2001, pp. 856S-864S
Authors:
Shabat, D
Lode, HN
Pertl, U
Reisfeld, RA
Rader, C
Lerner, RA
Barbas, CF
Citation: D. Shabat et al., In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy, P NAS US, 98(13), 2001, pp. 7528-7533
Authors:
Pertl, U
Luster, AD
Varki, NM
Homann, D
Gaedicke, G
Reisfeld, RA
Lode, HN
Citation: U. Pertl et al., IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy, J IMMUNOL, 166(11), 2001, pp. 6944-6951
Authors:
Lode, HN
Pertl, U
Xiang, R
Gaedicke, G
Reisfeld, RA
Citation: Hn. Lode et al., Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma, MED PED ONC, 35(6), 2000, pp. 641-646
Authors:
Balicki, D
Reisfeld, RA
Pertl, U
Beutler, E
Lode, HN
Citation: D. Balicki et al., Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma, P NAS US, 97(21), 2000, pp. 11500-11504
Authors:
Lode, HN
Xiang, R
Perri, P
Pertl, U
Lode, A
Gillies, SD
Reisfeld, RA
Citation: Hn. Lode et al., What to do with targeted IL-2, DRUGS TODAY, 36(5), 2000, pp. 321-336
Authors:
Lode, HN
Xiang, R
Pertl, U
Forster, E
Schoenberger, SP
Gillies, SD
Reisfeld, RA
Citation: Hn. Lode et al., Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction, J CLIN INV, 105(11), 2000, pp. 1623-1630
Risultati:
1-7
|